NDX-1017 Phase 1 Trial Complete, Results Will Be Presented at CTAD Conference, Athira Says

NDX-1017 Phase 1 Trial Complete, Results Will Be Presented at CTAD Conference, Athira Says
Athira Pharma has completed the Phase 1 trial testing NDX-1017, its lead therapeutic candidate for Alzheimer’s disease, and will present the results at the 12th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference in December. Preliminary results showed the therapy, which has the potential to be regenerative and to slow or stop disease progression, to be safe and well-tolerated. Hans J. Moebius, MD, PhD, Athira's chief medical officer, will present the trial's final results during the CTAD Conference, which will take place in San Diego Dec. 4-7. "NDX-1017 represents a new approach to the treatment of neurodegenerative diseases like Alzheimer's. Completing our first clinical trial is a momentous event, and we look forward to the presentation of data from this trial later this year," Moebius said in a press release. The investigational medication is a small therapeutic molecule designed to increase the activity of the hepatocyte growth factor (HGF, also known as scatter factor), and its receptor protein MET. Known for its role in liver regeneration, several studies have reported that HGF-MET also can regulate various brain functions, including axonal growth — the long projections of nerve cells that allow them to communicate — neuronal survival, and transmission of informat
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *